Park Jae, Singh Bhag, Gupta Radhey S
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
Mol Cell Biochem. 2006 Feb;283(1-2):11-21. doi: 10.1007/s11010-006-2216-7.
The enzyme adenosine kinase (AK) plays a central role in regulating the intracellular and interstitial concentration of the purine nucleoside adenosine (Ado). In view of the beneficial effects of Ado in protecting tissues from ischemia and other stresses, there is much interest in developing AK inhibitors, which can regulate Ado concentration in a site- and event-specific manner. The catalytic activity of AK from different sources is dependent upon the presence of activators such as phosphate (Pi). In this work we describe several new phosphorylated compounds which either activate or inhibit AK. The compounds acetyl phosphate, carbamoyl phosphate, dihydroxyacetone phosphate and imidodiphosphate were found to stimulate AK activity in a dose-dependent manner comparable to that seen with Pi. In contrast, a number of phosphonate and bisphosphonate derivatives, which included clodronate and etidronate, were found to inhibit the activity of purified AK in the presence of Pi. These AK inhibitors (viz. clodronate, etidronate, phosphonoacetic acid, 2-carboxyethylphosphonic acid, N-(phosphonomethyl)-glycine and N-(phosphonomethyl)iminodiacetic acid), at concentrations at which they inhibited AK, were also shown to inhibit the uptake of (3)H-adenosine and its incorporation into macromolecules in cultured mammalian cells, indicating that they were also inhibiting AK in intact cells. The drug concentrations at which these effects were observed showed limited toxicity to the cultured cells, indicating that these effects are not caused by cellular toxicity. These results indicate that the enzyme AK provides an additional cellular target for the clinically widely used bisphosphonates and related compounds, which could possibly be exploited for a new therapeutic application. Our structure-activity studies on different AK activators and inhibitors also indicate that all of the AK activating compounds have a higher partial positive charge (delta(+)) on the central phosphorous atom in comparison to the inhibitors. This information should prove helpful in the design and synthesis of more potent inhibitors of AK.
腺苷激酶(AK)在调节嘌呤核苷腺苷(Ado)的细胞内和细胞间浓度方面发挥着核心作用。鉴于Ado在保护组织免受缺血和其他应激方面的有益作用,人们对开发AK抑制剂非常感兴趣,这些抑制剂可以以位点和事件特异性的方式调节Ado浓度。来自不同来源的AK的催化活性取决于激活剂如磷酸盐(Pi)的存在。在这项工作中,我们描述了几种新的磷酸化化合物,它们要么激活要么抑制AK。发现乙酰磷酸、氨基甲酰磷酸、磷酸二羟丙酮和亚氨二磷酸以剂量依赖性方式刺激AK活性,其程度与Pi相当。相比之下,发现一些膦酸盐和双膦酸盐衍生物,包括氯屈膦酸盐和依替膦酸盐,在有Pi存在的情况下抑制纯化的AK的活性。这些AK抑制剂(即氯屈膦酸盐、依替膦酸盐、膦酰乙酸、2-羧乙基膦酸、N-(膦酰甲基)-甘氨酸和N-(膦酰甲基)亚氨基二乙酸)在抑制AK的浓度下,也显示出抑制培养的哺乳动物细胞中(3)H-腺苷的摄取及其掺入大分子,表明它们也在完整细胞中抑制AK。观察到这些作用的药物浓度对培养细胞显示出有限的毒性,表明这些作用不是由细胞毒性引起的。这些结果表明,AK酶为临床广泛使用的双膦酸盐和相关化合物提供了一个额外的细胞靶点,这可能被用于新的治疗应用。我们对不同AK激活剂和抑制剂的构效关系研究还表明,与抑制剂相比,所有AK激活化合物在中心磷原子上具有更高的部分正电荷(δ(+))。这些信息在设计和合成更有效的AK抑制剂方面应该会有所帮助。